A phase I trial assessing the safety, pharmacokinetics, cerebrospinal fluid penetrance, and food effect of BTK inhibitor tolebrutinib in healthy volunteers

• Principais autores: Marie‐José Cabanis (Autor), Olivier Nicolas (Autor), Olivier Vitse (Autor), Christelle Jan (Autor), Priscilla Brun (Autor), Patrick Soubayrol (Autor), William B. Smith (Autor), Timothy J. Turner (Autor), Emmanuel Krupka (Autor)
• Formato: Livro
• Publicado em: Wiley, 2024-02-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

Abstract Tolebrutinib is an oral, brain‐penetrant, covalent Bruton's tyrosine kinase inhibitor in development to treat multiple sclerosis at 60 mg/day with food. A phase I trial was conducted in healthy volunteers to assess the safety and pharmacokinetics of tolebrutinib at oral doses higher th...